Code	GD1009-RV (GeneDetect® rAVE™ Gene Delivery Reagent)
Vector	AAV1/2-CAG-**Scrambled Control 3XmiR/GFP**-WPRE-BGH-polyA
Vector Description	AAV1/2 Vector. miR scrambled control x3 co-expressing eGFP. The CAG promoter consists of the chicken β-actin promoter hybridized with the CMV immediate early enhancer sequence and is highly efficient in most tissue types. The Woodchuck post-transcriptional regulatory element (WPRE) and the presence of a bovine growth hormone (BGH) polyadenylation sequence ensures high transcription following transduction.
Lot Number	32087
Quantity	0.1 ml (100 µl)
Purity	Iodixanol gradient
Titer/Concentration	3.85×10^{11} GC/ml Titered by QPCR by Vigene Biosciences
Product Manufacturer	GeneDetect® www.GeneDetect.com
Presentation	Liquid in phosphate buffered saline (PBS) containing 1mM $MgCl_2$ and Lutrol F68 (0.001%)
Storage & Stability	Upon receipt, briefly spin contents of vial to collect sample, aliquot on ice under sterile conditions and store: 4°C for short term (<1 month), -20°C or -80°C for long term. Avoid repeated freeze-thaw cycles.

Quality Control 10µl was analyzed by SDS-PAGE to verify purity.



Handling Always wear laboratory gloves, protective glasses and a suitable protective laboratory coat when using rAVE™ reagents. Recent NIH guidelines state that "adeno-associated virus (AAV) types 1 through 4, and recombinant AAV constructs, in which the transgene does not encode either a potentially tumorigenic gene product or a toxin molecule and are produced in the absence of a helper virus" can in most cases be handled at biosafety level 1 (BL1). You should follow the guidelines set by your Institutional biosafety committee for the handling of adeno-associated virus.

Disposal rAVE™ reagents are susceptible to 5% phenol, 10% bleach, 10% Wescodyne, or Virkon. We recommend using a fresh solution of 10% bleach for 30 minutes for decontamination.

Applications For *in vitro* applications, mix 2µl rAVE™ sample with 200µl pre-warmed culture media and apply per well to cells of 60 – 80% confluency (24well plate). Allow at least three days for viral integration and gene expression before analysis. For *in vivo* applications, dose should be determined by end user.

References For a comprehensive list of references refer to www.GeneDetect.com

Initial Characterization Data Refer to The Michael J. Fox Foundation Research Tools webpage for *in vitro* and *in vivo* characterization data.

For research use only, not for clinical or diagnostic use.